// App-Quantinova.ai

6518 : Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis.

Researchers

Presenter

  • Daniel A. Goldstein

Principal Investigators

  • Qiushi Chen

  • Turgay Ayer

  • Kelvin K. Chan

  • Kiran Virik

  • Ariel Hammerman

  • Baruch Brenner

  • Christopher Flowers

  • Peter Hall

Medical Centers

  • Davidoff Center, Rabin Medical Center, Petach-Tikva, Israel

  • H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA

  • Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Department of Medicine, University of Tasmania, Tasmania, Australia

  • Chief Physician's Office, Clalit Health Services Headquarters, Tel-Aviv, Israel

  • Rabin Medical Center, Petach Tikvah, Israel

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom

Locations

  • Canada

  • United Kingdom

  • Australia

  • United States

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Bevacizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved